F Schlegel

Suggest Changes
  • Citations Per Year
Learn More
Background This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with(More)
  • 1